Have any questions? 706-721-6582 or cts@augusta.edu
- (ROP) Randomized, Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients with Retinopathy of Prematurity
Clinical Trial
(ROP) Randomized, Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients with Retinopathy of Prematurity
This study will compare two ways of treating an eye disease that happens with some premature infants. This disease is called retinopathy of prematurity, or ROP. Laser therapy is the usual treatment. A drug, aflibercept, will be used in some infants instead of laser therapy. Aflibercept is used now to treat diseases of the retina in adults.
Eligibility Criteria
- male and female neonates gestational age at birth of 32 weeks or less, or with birth weight of 1500 grams or less with untreated retinopathy of prematurity (ROP) in at least one eye able to tolerate repeated blood draws who are otherwise healthy and without chormosomal anomalies
RESEARCH. INNOVATION. DISCOVERY.